BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 16622122)

  • 21. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
    Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
    J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
    J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.
    Sterling WA; Weiner J; Schreiber D; Mehta K; Weiss JP
    Int Urol Nephrol; 2016 Dec; 48(12):2015-2021. PubMed ID: 27580731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
    Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
    Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
    Potter SR; Horniger W; Tinzl M; Bartsch G; Partin AW
    Urology; 2001 Jun; 57(6):1100-4. PubMed ID: 11377318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.
    Eastham JA; May R; Robertson JL; Sartor O; Kattan MW
    Urology; 1999 Oct; 54(4):709-13. PubMed ID: 10510933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of lower urinary tract symptoms is an independent predictor for cancer at prostate biopsy, but prostate-specific antigen is not: results from a prospective series of 569 patients.
    Porter CR; Latchamsetty KC; Coogan CL; Kim J
    Clin Prostate Cancer; 2005 Jun; 4(1):50-4. PubMed ID: 15992462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
    Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
    J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.
    Ross LE; Taylor YJ; Richardson LC; Howard DL
    J Natl Med Assoc; 2009 Apr; 101(4):316-24. PubMed ID: 19397221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.
    Walsh AL; Considine SW; Thomas AZ; Lynch TH; Manecksha RP
    Br J Gen Pract; 2014 Dec; 64(629):e783-7. PubMed ID: 25452543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
    Freedland SJ; Hamilton RJ; Gerber L; Banez LL; Moreira DM; Andriole GL; Rittmaster RS
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):254-9. PubMed ID: 23567655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population.
    Lienert AR; Davidson PJ; Wells JE
    N Z Med J; 2009 Jan; 122(1288):39-49. PubMed ID: 19182841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH
    Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997.
    Roberts RO; Bergstralh EJ; Lieber MM; Jacobsen SJ
    Urology; 2000 Nov; 56(5):817-22. PubMed ID: 11068309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.